Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 420

Similar articles for PubMed (Select 9337447)

1.

New pharmacotherapy for Parkinson's disease.

Gottwald MD, Bainbridge JL, Dowling GA, Aminoff MJ, Alldredge BK.

Ann Pharmacother. 1997 Oct;31(10):1205-17. Review.

PMID:
9337447
2.

New options for treatment of Parkinson's disease.

LeWitt PA.

Baillieres Clin Neurol. 1997 Apr;6(1):109-23. Review.

PMID:
9426871
3.

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

Deane KH, Spieker S, Clarke CE.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004554. Review.

PMID:
15495119
4.
5.

Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.

Deane KH, Spieker S, Clarke CE.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004553. Review.

PMID:
15495118
6.

Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.

Inzelberg R, Schechtman E, Nisipeanu P.

Drugs Aging. 2003;20(11):847-55. Review.

PMID:
12964891
7.

Clinical pharmacology of dopamine agonists in Parkinson's disease.

Lange KW.

Drugs Aging. 1998 Nov;13(5):381-9. Review.

PMID:
9829165
8.

COMT inhibition in the treatment of Parkinson's disease.

Ruottinen HM, Rinne UK.

J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. Review.

PMID:
9808337
9.

[Recent advances in Parkinson disease].

Litvan I.

Rev Neurol. 1999 Jul 16-31;29(2):139-45. Review. Spanish.

PMID:
10528328
10.

Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.

Widnell KL, Comella C.

Mov Disord. 2005;20 Suppl 11:S30-7. Review.

PMID:
15822107
11.
12.

Treatment of Parkinson's disease should begin with a dopamine agonist.

Montastruc JL, Rascol O, Senard JM.

Mov Disord. 1999 Sep;14(5):725-30. Review.

PMID:
10495032
13.

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Dooley M, Markham A.

Drugs Aging. 1998 Jun;12(6):495-514. Review.

PMID:
9638397
14.

Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Nyholm D.

Clin Pharmacokinet. 2006;45(2):109-36. Review.

PMID:
16485914
15.
16.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2001;(1):CD001516. Review.

PMID:
11279718
17.

[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].

Krivonos OV, Fedorova NV, Chigir' IP.

Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(1):24-30. Russian.

PMID:
14870689
18.

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Deleu D, Northway MG, Hanssens Y.

Clin Pharmacokinet. 2002;41(4):261-309. Review.

PMID:
11978145
19.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001516. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001516.

PMID:
10908503
20.

New drugs for the treatment of Parkinson's disease.

LeWitt PA.

Pharmacotherapy. 2000 Jan;20(1 Pt 2):26S-32S. Review.

PMID:
10641989
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk